



Celentyx Ltd News Release
3rd January 2008

Celentyx announces collaboration with Schering-Plough

Celentyx Ltd, a leader in the field of Neuroimmunopharmacology, announced today that Schering-Plough has signed an agreement to utilise Immuno-Profiling™ to support the R&D of novel drug targets.

"We are delighted to have the opportunity to work with Schering-Plough" said Nicholas Barnes, CEO of Celentyx. "This further confirms the utility of our unique Immuno-Profiling™ technology".

Dr Marianthi Papakosta of Schering-Plough said "This exciting collaboration between Schering-Plough and Celentyx Ltd allows us access to Immuno-Profiling™; a range of powerful, intelligent, proprietary platform screening methodologies using human immune cells. Of particular importance to Schering-Plough is that we will gain access to, and learn from the experience and valuable advice of recognised international experts of human immune cell function. Finally, we anticipate this partnership with Celentyx Ltd will place Schering-Plough at the forefront of the new and developing field of Neuroimmunopharmacology."

ENDS

Further information:

Dr Nicholas Barnes – CEO, Celentyx Ltd
Tel: +44 (0)121 414 4499 / Mob: +44 (0)7973 191 822
Email: nicholas.barnes@celentyx.com

NOTES TO EDITORS

Celentyx

Celentyx Ltd is an R&D-based company with a focus on human immune disease. Dysfunction of the immune system underlies numerous diseases including lymphoma, leukaemia, inflammation, allergy and autoimmune diseases. As key effectors within the immune system, lymphocytes are highly attractive targets for drug candidates in a wide variety of common life-debilitating or life-threatening diseases.

A spin-out from the University of Birmingham Medical School, Celentyx technology and expertise originated from the laboratories of Dr Nicholas Barnes and Prof John Gordon. Amongst the first in the world to recognise that many neurotransmitters also modify the immune system, Dr Barnes and Prof Gordon are internationally recognised authorities in this relatively new field of Neuroimmunopharmacology.